Skip to main content
Premium Trial:

Request an Annual Quote

Clearing Hurdles, Nanogen and Epoch Shareholders OK Acquisition

NEW YORK, Dec. 16 (GenomeWeb News) - Nanogen and Epoch Biosciences shareholders yesterday finally approved Nanogen's acquisition of Epoch for $97 million. The deal, originally announced in Spetember, is expected to close today.


Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company's certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million shares.


Epoch Biosciences is expected to cease trading on the Nasdaq exchange at market close on Thursday afternoon.


Epoch stockholders will receive .47 shares of Nanogen stock in exchange for each share of Epoch common stock they hold. At the completion of the merger, Nanogen will have approximately 50 million common shares outstanding.


The Nanogen shareholder meeting was originally held on Dec. 8, but was postponed until Dec. 15 because the number of shares represented by votes or votes by proxy was insufficient for a decision.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.